首页> 美国卫生研究院文献>Retrovirology >Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV-1 latency
【2h】

Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV-1 latency

机译:在HIV-1潜伏期的细胞模型中用组蛋白脱乙酰基酶(HDAC)抑制剂治疗不会诱导人内源性逆转录病毒(HERV)表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background While antiretroviral therapies have improved life expectancy and reduced viral loads in HIV-1-positive individuals, the cessation of treatment results in a rebound of viral replication. This suggests that a reservoir of latently-infected cells remains within these patients, the identity of which is ill-defined and therefore difficult to target therapeutically. Current strategies are aimed at using drugs such as histone deacetylase (HDAC) inhibitors to induce the expression of latent HIV-1 proviruses in order to activate and ultimately eradicate this reservoir of infected cells. One concern with the use of HDAC inhibitors is that they could up-regulate human endogenous retroviruses (HERVs), as well as HIV-1, with potentially pathophysiological consequences.
机译:背景技术虽然抗逆转录病毒疗法可以改善HIV-1阳性个体的预期寿命并减少病毒载量,但停止治疗会导致病毒复制反弹。这表明这些患者中仍保留有潜伏感染细胞的库,其身份不清楚,因此难以靶向治疗。当前的策略旨在使用诸如组蛋白脱乙酰基酶(HDAC)抑制剂之类的药物来诱导潜在的HIV-1前病毒的表达,从而激活并最终消除感染细胞的这一库。使用HDAC抑制剂的一个问题是,它们可能会上调人类内源性逆转录病毒(HERV)以及HIV-1,从而具有潜在的病理生理后果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号